Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1

Anna M. Furimsky, Carol E. Green, Lewanne E. Hunt Sharp, Paul Catz, Araba A. Adjei, Toufan Parman, Izet M. Kapetanovic, Richard M Weinshilboum, Lalitha V. Iyer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The purpose of this study was to investigate the sulfation of resveratrol (3,5,4′-trihydroxystilbene) and its potential to exhibit drug-drug interactions via sulfation. The possible interaction of resveratrol with 17β-estradiol (E2), a major estrogen hormone and prototypic substrate for sulfate conjugation, was studied. Resveratrol and E2 are both known to undergo sulfate conjugation catalyzed by human sulfotransferases (SULTs). Resveratrol is a phytoestrogen with mixed estrogen agonist/antagonist properties that is being developed as a chemopreventive agent. The sulfate conjugation of E2 and resveratrol were studied individually using S9 fractions from human liver and jejunum as well as recombinant human SULT isoforms. The sulfation of E2 (3-20 nM) was then investigated in the presence of various concentrations (0, 0.5, 1, and 2 μM) of resveratrol using the two S9 preparations as well as recombinant SULT1E1, the major isoform responsible for E2 sulfation. Resveratrol inhibited E2 sulfation with estimated Ki values of 1.1 μM (liver), 0.6 μM (jejunum), and 2.3 μM (SULT1E1), concentrations that could be pharmacologically relevant. The results suggest that these phytoestrogens can potentially alter the homeostasis of estrogen levels. These findings also imply that resveratrol may inhibit the metabolism of other estrogen analogs or therapeutic agents such as ethinylestradiol or dietary components that are also substrates for SULT1E1.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalDrug Metabolism and Disposition
Volume36
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Sulfotransferases
Estradiol
Liver
Sulfates
Phytoestrogens
Estrogens
Jejunum
Protein Isoforms
Drug interactions
Estradiol Congeners
Estrogen Antagonists
resveratrol
Ethinyl Estradiol
Substrates
Drug Interactions
Metabolism
Homeostasis
Hormones

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology
  • Medicine(all)

Cite this

Furimsky, A. M., Green, C. E., Hunt Sharp, L. E., Catz, P., Adjei, A. A., Parman, T., ... Iyer, L. V. (2008). Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug Metabolism and Disposition, 36(1), 129-136. https://doi.org/10.1124/dmd.107.016725

Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. / Furimsky, Anna M.; Green, Carol E.; Hunt Sharp, Lewanne E.; Catz, Paul; Adjei, Araba A.; Parman, Toufan; Kapetanovic, Izet M.; Weinshilboum, Richard M; Iyer, Lalitha V.

In: Drug Metabolism and Disposition, Vol. 36, No. 1, 01.2008, p. 129-136.

Research output: Contribution to journalArticle

Furimsky, AM, Green, CE, Hunt Sharp, LE, Catz, P, Adjei, AA, Parman, T, Kapetanovic, IM, Weinshilboum, RM & Iyer, LV 2008, 'Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1', Drug Metabolism and Disposition, vol. 36, no. 1, pp. 129-136. https://doi.org/10.1124/dmd.107.016725
Furimsky, Anna M. ; Green, Carol E. ; Hunt Sharp, Lewanne E. ; Catz, Paul ; Adjei, Araba A. ; Parman, Toufan ; Kapetanovic, Izet M. ; Weinshilboum, Richard M ; Iyer, Lalitha V. / Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. In: Drug Metabolism and Disposition. 2008 ; Vol. 36, No. 1. pp. 129-136.
@article{e4e4c047a28644faabb3538f5e941d95,
title = "Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1",
abstract = "The purpose of this study was to investigate the sulfation of resveratrol (3,5,4′-trihydroxystilbene) and its potential to exhibit drug-drug interactions via sulfation. The possible interaction of resveratrol with 17β-estradiol (E2), a major estrogen hormone and prototypic substrate for sulfate conjugation, was studied. Resveratrol and E2 are both known to undergo sulfate conjugation catalyzed by human sulfotransferases (SULTs). Resveratrol is a phytoestrogen with mixed estrogen agonist/antagonist properties that is being developed as a chemopreventive agent. The sulfate conjugation of E2 and resveratrol were studied individually using S9 fractions from human liver and jejunum as well as recombinant human SULT isoforms. The sulfation of E2 (3-20 nM) was then investigated in the presence of various concentrations (0, 0.5, 1, and 2 μM) of resveratrol using the two S9 preparations as well as recombinant SULT1E1, the major isoform responsible for E2 sulfation. Resveratrol inhibited E2 sulfation with estimated Ki values of 1.1 μM (liver), 0.6 μM (jejunum), and 2.3 μM (SULT1E1), concentrations that could be pharmacologically relevant. The results suggest that these phytoestrogens can potentially alter the homeostasis of estrogen levels. These findings also imply that resveratrol may inhibit the metabolism of other estrogen analogs or therapeutic agents such as ethinylestradiol or dietary components that are also substrates for SULT1E1.",
author = "Furimsky, {Anna M.} and Green, {Carol E.} and {Hunt Sharp}, {Lewanne E.} and Paul Catz and Adjei, {Araba A.} and Toufan Parman and Kapetanovic, {Izet M.} and Weinshilboum, {Richard M} and Iyer, {Lalitha V.}",
year = "2008",
month = "1",
doi = "10.1124/dmd.107.016725",
language = "English (US)",
volume = "36",
pages = "129--136",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Effect of resveratrol on 17β-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1

AU - Furimsky, Anna M.

AU - Green, Carol E.

AU - Hunt Sharp, Lewanne E.

AU - Catz, Paul

AU - Adjei, Araba A.

AU - Parman, Toufan

AU - Kapetanovic, Izet M.

AU - Weinshilboum, Richard M

AU - Iyer, Lalitha V.

PY - 2008/1

Y1 - 2008/1

N2 - The purpose of this study was to investigate the sulfation of resveratrol (3,5,4′-trihydroxystilbene) and its potential to exhibit drug-drug interactions via sulfation. The possible interaction of resveratrol with 17β-estradiol (E2), a major estrogen hormone and prototypic substrate for sulfate conjugation, was studied. Resveratrol and E2 are both known to undergo sulfate conjugation catalyzed by human sulfotransferases (SULTs). Resveratrol is a phytoestrogen with mixed estrogen agonist/antagonist properties that is being developed as a chemopreventive agent. The sulfate conjugation of E2 and resveratrol were studied individually using S9 fractions from human liver and jejunum as well as recombinant human SULT isoforms. The sulfation of E2 (3-20 nM) was then investigated in the presence of various concentrations (0, 0.5, 1, and 2 μM) of resveratrol using the two S9 preparations as well as recombinant SULT1E1, the major isoform responsible for E2 sulfation. Resveratrol inhibited E2 sulfation with estimated Ki values of 1.1 μM (liver), 0.6 μM (jejunum), and 2.3 μM (SULT1E1), concentrations that could be pharmacologically relevant. The results suggest that these phytoestrogens can potentially alter the homeostasis of estrogen levels. These findings also imply that resveratrol may inhibit the metabolism of other estrogen analogs or therapeutic agents such as ethinylestradiol or dietary components that are also substrates for SULT1E1.

AB - The purpose of this study was to investigate the sulfation of resveratrol (3,5,4′-trihydroxystilbene) and its potential to exhibit drug-drug interactions via sulfation. The possible interaction of resveratrol with 17β-estradiol (E2), a major estrogen hormone and prototypic substrate for sulfate conjugation, was studied. Resveratrol and E2 are both known to undergo sulfate conjugation catalyzed by human sulfotransferases (SULTs). Resveratrol is a phytoestrogen with mixed estrogen agonist/antagonist properties that is being developed as a chemopreventive agent. The sulfate conjugation of E2 and resveratrol were studied individually using S9 fractions from human liver and jejunum as well as recombinant human SULT isoforms. The sulfation of E2 (3-20 nM) was then investigated in the presence of various concentrations (0, 0.5, 1, and 2 μM) of resveratrol using the two S9 preparations as well as recombinant SULT1E1, the major isoform responsible for E2 sulfation. Resveratrol inhibited E2 sulfation with estimated Ki values of 1.1 μM (liver), 0.6 μM (jejunum), and 2.3 μM (SULT1E1), concentrations that could be pharmacologically relevant. The results suggest that these phytoestrogens can potentially alter the homeostasis of estrogen levels. These findings also imply that resveratrol may inhibit the metabolism of other estrogen analogs or therapeutic agents such as ethinylestradiol or dietary components that are also substrates for SULT1E1.

UR - http://www.scopus.com/inward/record.url?scp=37549003662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549003662&partnerID=8YFLogxK

U2 - 10.1124/dmd.107.016725

DO - 10.1124/dmd.107.016725

M3 - Article

VL - 36

SP - 129

EP - 136

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -